Agios Pharmaceuticals' (AGIO) Hold (C-) Rating Reiterated at Weiss Ratings

Key Points

• Weiss Ratings has reiterated a "hold (C-)" rating for Agios Pharmaceuticals (AGIO) in its latest research report, while other analysts have provided mixed ratings, with Zacks Research downgrading the stock to a "strong sell."
• Shares of Agios Pharmaceuticals rose by 3.4%, reaching $42.25, and have a market cap of $2.45 billion with a P/E ratio of 3.85.
• In recent insider trading activity, CEO Brian Goff sold over 11,000 shares, reducing his stake by 8.23%, while institutional investors have also increased their holdings in the company.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report)'s stock had its "hold (c-)" rating reissued by Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

AGIO has been the topic of a number of other research reports. Zacks Research lowered shares of Agios Pharmaceuticals from a "hold" rating to a "strong sell" rating in a report on Monday. Bank of America cut their price target on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Scotiabank cut their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a report on Monday, July 28th. Finally, HC Wainwright reiterated a "buy" rating and set a $56.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, September 4th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $56.00.

Agios Pharmaceuticals Stock Up 3.4%

Shares of NASDAQ AGIO traded up $1.38 during midday trading on Wednesday, reaching $42.25. 246,074 shares of the company were exchanged, compared to its average volume of 706,540. The stock's 50-day moving average price is $37.57 and its 200-day moving average price is $33.96. The stock has a market cap of $2.45 billion, a P/E ratio of 3.85 and a beta of 0.83. Agios Pharmaceuticals has a one year low of $23.42 and a one year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. On average, equities research analysts anticipate that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,085 shares of the company's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $36.67, for a total value of $406,486.95. Following the completion of the sale, the chief executive officer directly owned 123,528 shares of the company's stock, valued at approximately $4,529,771.76. This represents a 8.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Theodore James Jr. Washburn sold 8,546 shares of the company's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $36.87, for a total transaction of $315,091.02. Following the completion of the sale, the insider directly owned 868 shares of the company's stock, valued at $32,003.16. The trade was a 90.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 24,682 shares of company stock valued at $911,825. Insiders own 4.93% of the company's stock.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Assenagon Asset Management S.A. purchased a new stake in shares of Agios Pharmaceuticals during the 3rd quarter valued at approximately $2,696,000. Hudson Bay Capital Management LP lifted its stake in shares of Agios Pharmaceuticals by 17.4% during the 2nd quarter. Hudson Bay Capital Management LP now owns 130,000 shares of the biopharmaceutical company's stock valued at $4,324,000 after buying an additional 19,280 shares in the last quarter. Headlands Technologies LLC lifted its stake in shares of Agios Pharmaceuticals by 18.0% during the 2nd quarter. Headlands Technologies LLC now owns 12,644 shares of the biopharmaceutical company's stock valued at $421,000 after buying an additional 1,929 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Agios Pharmaceuticals by 634.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,440 shares of the biopharmaceutical company's stock valued at $214,000 after buying an additional 5,563 shares in the last quarter. Finally, Two Sigma Securities LLC purchased a new stake in Agios Pharmaceuticals in the 2nd quarter worth approximately $288,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.